Medicus Pharma Advances Teverelix Phase 2 Study with FDA Feedback and IRB Approval
Event summary
- Medicus Pharma received positive FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix® in acute urinary retention (AUR).
- The redesigned ANT-2111-02 study will enroll approximately 126 patients, down from the originally planned 390.
- FDA's feedback included seven operational recommendations, none requiring changes to the study's scientific rationale or primary endpoint.
- Central IRB approval was received on June 18, 2026, with modifications related to informed consent templates.
The big picture
Medicus Pharma's streamlined Phase 2 study design reflects a broader trend in biotech toward capital-efficient clinical development. The FDA's operational feedback suggests regulatory flexibility for studies targeting unmet needs like recurrent AUR, potentially accelerating pathways for novel therapies. The company's ability to reduce enrollment by two-thirds while maintaining decision-grade evidence could set a precedent for similar mid-stage trials.
What we're watching
- Execution Risk
- Whether Medicus can efficiently incorporate FDA recommendations and initiate the study as planned.
- Clinical Strategy
- How the reduced patient enrollment will impact the robustness of the pharmacodynamic signal and dose optimization.
- Partnering Opportunities
- The pace at which Medicus can leverage this optimized dataset to attract strategic partners for Teverelix® development.
Related topics